Format

Send to

Choose Destination
Cancer Lett. 2009 Aug 8;280(2):211-21. doi: 10.1016/j.canlet.2009.02.013. Epub 2009 Mar 16.

Isoform-specific histone deacetylase inhibitors: the next step?

Author information

1
Department of Cancer Biology, Pharmacyclics, Inc, Sunnyvale, CA 94085, United States. sriram@pcyc.com

Abstract

Histone deacetylases (HDACs) have emerged as attractive drug targets, particularly for neoplastic indications. This large family is divided into four classes, of which three consist of zinc-dependent enzymes, and inhibitors of these are the subject of this review. Currently, there are several inhibitors advancing through clinical trials, all of which inhibit multiple isoforms of these three classes. While promising, these compounds have exhibited toxicities in the clinic that might limit their potential, particularly in solid tumors. It may be possible to reduce some of the toxicity by specifically targeting only the isoform(s) involved in maintaining that particular tumor and spare other isoforms that are uninvolved or even beneficial. This review examines the selectivity and toxicity of HDAC inhibitors currently in clinic, comparing pan-HDAC inhibitors to Class I selective compounds. The rationale for isoform-specific inhibitors is examined. The current status of isoform-specific inhibitor development is analyzed, especially inhibitors of HDAC1, 2, 4 and 8 enzymes, and the potential clinical utility of these compounds is discussed.

PMID:
19289255
DOI:
10.1016/j.canlet.2009.02.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center